Relapsed or Refractory Hodgkin Lymphoma
Conditions
Keywords
R/R Hodgkin lymphoma, Brentuximab-vedotin
Brief summary
Approximately 20% of patients diagnosed with Hodgkin lymphoma will eventually experience progression or relapse after first-line treatment, which carries a significant risk of disease-related death. Although several pilot studies have demonstrated high rates of sustained response with the combination of brentuximab vedotin (BV) and chemotherapy, consistent real-world data are still lacking. Moreover, there is no universally accepted salvage chemotherapy regimen in this setting, and clinical practices vary across centers. This study aims to describe the efficacy and toxicity of the BV + bendamustine (B2) regimen in patients with relapsed/refractory Hodgkin lymphoma (R/R HL) treated in France over a 10-year period, with or without an attempt at consolidative transplantation.
Detailed description
This study is a retrospective observational multicentric study. All patients fulfilling inclusion criteria in participant centers will be included. Clinical data will be obtained from patients medical records.
Interventions
DRUGBrentuximab-Vedotin associated with Bendamustine
Patient having received at least one course of the association Brentuximab-Vedotin and Bendamustine
Sponsors
University Hospital, Bordeaux
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient with relapsed or refractory HL, after at least one first line of treatment * Aged 18 years and over * Having received at least one course of the Brenxutimab-Vedotin J1 and Bendamustine J1 + J2 combination
Exclusion criteria
* Minor patients * Pregnant women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival (PFS) for the whole cohort | From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months | Measured from the time of treatment initiation to the date of event : progression or death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overal survival (OS) for the whole cohort | From date of inclusion until the date of death from any cause assessed up to 120 months | Measured from the time of treatment initiation to the date of death |
Countries
France
Outcome results
None listed